Piv­otal da­ta ce­ment use of In­cyte, No­var­tis' rux­oli­tinib in dif­fi­cult-to-treat graft-ver­sus-host dis­ease

6 years ago
R&D
Pharma

Bain helps push Affini­vax to next stage with $120M round, as PhII da­ta loom on a lead ef­fort to do some­thing new in ...

6 years ago
Financing
R&D

Sanofi steps up with its da­ta on a new MS drug, shin­ing a spot­light on PhI­II hopes af­ter fend­ing off a short at­tack

6 years ago
R&D

De­posed BAR­DA chief blasts Trump ad­min­is­tra­tion on pro­mot­ing un­proven drugs as Covid-19 panacea: 'Science — not ...

6 years ago
People
Coronavirus

Ven­rock joins the biotech VC fundrais­ing game, toss­ing $447M in­to a $4.3B pot of new mon­ey

6 years ago
Financing

Analy­sis shows Swiss biotech in­dex out­shines Nas­daq coun­ter­part, but coro­n­avirus chal­lenges are uni­ver­sal

6 years ago
Financing
R&D

Over a year af­ter re­jec­tion, Im­munomedics emerges with po­ten­tial block­buster ap­proval

6 years ago
Pharma
FDA+

Big Phar­ma VC firms put $11M in seed funds be­hind can­cer start­up with bold vi­sion

6 years ago
Financing
Startups

EMA ap­proves Boehringer's sys­temic scle­ro­sis ther­a­py; No­var­tis' Kym­ri­ah wins RMAT sta­tus for fol­lic­u­lar lym­phoma

6 years ago
News Briefing

A long­time Lau­ra Shawver fan calls the se­r­i­al en­tre­pre­neur back to the helm of a biotech up­start

6 years ago
People
Startups

‘Break­through’ drugs in­clud­ed on Roche’s list of PhII/III stud­ies axed in Q1 — with piv­otal Mir­ros tri­al on ...

6 years ago
R&D

First NDA in. Re­gion­al deal done. Now My­ovant has PhI­II da­ta to back up re­l­u­golix's push to an­oth­er block­buster ...

6 years ago
R&D

Bio­gen push­es back its time­line on the big ad­u­canum­ab FDA fil­ing as Covid-19 slows work — shares wilt

6 years ago
R&D

Covid-19 roundup: Carl June on hav­ing Covid-19 and his plan to treat it; NIH preach­es cau­tion; 2 new vac­cines en­ter ...

6 years ago
Coronavirus

Ab­b­Vie, J&J block­buster Im­bru­vi­ca rakes in 11th FDA ap­proval, as com­peti­tors work on erod­ing fran­chise

6 years ago
R&D
Pharma

Amid remde­sivir craze Gilead finds time for an­oth­er on­col­o­gy pact — loop­ing in all things NK cells

6 years ago
Deals

BAR­DA chief leaves po­si­tion as agency en­ters un­prece­dent­ed vac­cine cam­paign, rais­ing ques­tions about fed­er­al Covid-19 ...

6 years ago
People
Coronavirus

VA study spot­lights high­er death rate among Covid-19 pa­tients treat­ed with the con­tro­ver­sial drug hy­drox­y­chloro­quine

6 years ago
R&D
Coronavirus

Sang­amo ties up with a new­com­er in the cell ther­a­py field; Lab­Corp wins FDA au­tho­riza­tion of lat­est Covid-19 test

6 years ago
News Briefing

More pos­i­tive PhI­II da­ta set stage for Scynex­is' vagi­nal yeast in­fec­tion drug ap­proval

6 years ago
R&D

Astel­las snaps up mi­to­chon­dria-fo­cused biotech, beefs up drug dis­cov­ery in bud­get deal

6 years ago
Deals

Mer­ck KGaA adds to gene ther­a­py man­u­fac­tur­ing boom with €100M fa­cil­i­ty in Cal­i­for­nia

6 years ago
Cell/Gene Tx

Short at­tack tar­gets one of the fa­vorites now shar­ing the lead in the pop­u­lar KRAS drug de­vel­op­ment race

6 years ago
R&D

EMA up­dates on reg­u­la­to­ry ex­pec­ta­tions amid Covid-19

6 years ago
FDA+
Coronavirus
First page Previous page 854855856857858859860 Next page Last page
A service from the Financial Times